Long Term Impact of Implementation of a Stroke Protocol on Door to Needle Time in Administration of Intravenous Recombinant Tissue Plasmonigen Activator (IV-tPA) (P6.235)

CONCLUSIONS: Our study suggests that our performance in evaluating brain attack patients within the AHA/ASA suggested time window is reachable for prolonged periods of time. Continuous monitoring and education of all players involved is crucial to assure best possible outcomes in the administration of IV-tPADisclosure: Dr. He has nothing to disclose. Dr. Al-Qudah has nothing to disclose. Dr. Wang has nothing to disclose. Dr. Tank has nothing to disclose. Dr. Hillen has nothing to disclose.

Source: Neurology - April 8, 2015 Category: Neurology Authors: He, W., Al-Qudah, Z., Wang, W., Tank, V., Hillen, M. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Thrombolysis Source Type: research